Clinical data for CXCR4 inhibitor, Inlyta showa 29% ORR in clear cell renal cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

X4 Pharmaceuticals, a clinical stage biotechnology company developing a CXCR4 inhibitor to improve immune cell trafficking to treat cancer and rare diseases, announced updated results from the phase I part of an ongoing phase I/II study of X4P-001-IO in combination with Inlyta (axitinib) in patients with clear cell renal cell carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login